Novo Nordisk’s $10B bid beats Pfizer in obesity drug battle
The bidding war for obesity drugmaker Metsera just escalated dramatically. Novo Nordisk’s new $10 billion offer tops Pfizer’s $8.1 billion bid, with Metsera calling the Danish company’s proposal “superior” in the race for weight loss drug dominance.